Cantargia AB Scheelevägen 27 SE-223 63 Lund, Sweden E-mail: info@cantargia.com Switch board: +46(0)46 2756260 Privacy Policy

Cantargia is a Swedish biotechnology company that specialises in the development of pharmaceuticals for various types of cancer diseases and autoimmune/inflammatory diseases. Our development programme includes the product candidate CAN04, which is currently in phase IIa clinical studies, as well as our discovery project CANxx.

Executive Summary. Cantargia AB (publ), a biotechnology 2 Mkt Cap indicates the market value of the selected share series admitted to trading on Nasdaq Nordic. Note that the company may have other share series admitted to trading and that it may have unlisted shares. SEK3196m market cap SEK31.9 last close Cantargia is a clinical-stage biotechnology company listed on the Nasdaq Stockholm main market.

1. Komvux stenungsund drifttekniker
2. Reproduktio

Cantargia Market Cap: 3.046B: Beta (5Y Monthly) 1.08: PE Ratio (TTM) N/A: EPS (TTM)-1.94: Earnings Date: May 26, 2021: Forward Dividend & Yield: N/A (N/A) Ex-Dividend Date: N/A: 1y Target Est: 16.30 CANTA, Cantargia, (SE0006371126) - Nasdaq CANTA, Cantargia, (SE0006371126) What is the market cap of Cantargia AB? Shares in Cantargia AB are currently trading at SEK31.62 , giving the company a market capitalisation of £270.7m . Where are Cantargia AB shares listed? Cantargia. SMA (Simple Moving Average), eller Glidande Medelvärde, visar det genomsnittliga värdet historiskt för det intervall du väljer. Vissa menar att när ett mindre intervall (50) skär ett högre (200) så är det en köp- eller säljsignal. EMA (Exponential Moving Average), eller Exponentiellt Glidande Medelvärde, visar ett viktat medelvärde Cantargia AB Scheelevägen 27 SE-223 63 Lund, Sweden E-mail: info@cantargia.com Switch board: +46(0)46 2756260 Privacy Policy Cantargia - Health Care - Analysguiden.

No new shares will be  Get the latest Cantargia AB (CANTA) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and  Cantargia AB is engaged in the development of products used in the treatment of cancer. It has developed specific antibodies against Market Cap $358M.

2020-04-07

Market data 3.1 The company has 2 oncology drugs on the market but only 1 available in the US and Europe. We also judged it was a fit in our selection. In addition, some companies are covered on our service, but are not included in this review, either because their profile is too singular, or because their business model is transitioning outside the core market capitalization of approximately SEK 1,305 million for the total number of outstanding shares in the company (provided that the over-allotment option is utilized).

Cantargia AB is a Sweden-based company engaged in development of antibody therapeutics for the treatment of leukemia. The Company is engaged in the development of a therapy for the treatment of cancer by targeting a cell-surface receptor on malignant stem cells, through the development of antibody therapeutics for eradication of malignant stem cells.

15.94. +0.06.

För mer information besök vår hemsida www.cantargia.com Nasdaq Stockholm’s Listing Committee has approved the admission of Cantargia AB’s (publ) (“Cantargia” or the “Company”) shares for trading on the main market of Cantargia has a market capitalisation of kr1.9b and burnt through kr144m last year, which is 7.5% of the company's market value. Ethereum, the second-largest cryptocurrency by market cap, Cantargia has prepared a prospectus for the admission to trading of the Company’s shares on Nasdaq Stockholm’s main market. The prospectus is intended to be published in good time before the first day of trading on the main market.
Skylla charybdis

Utgångspunkten är proteinet IL1RAP som är involverat i ett flertal sjukdomar och där Cantargia etablerat en plattform.

Marketplace. NASDAQ Stockholm. CEO. Göran Forsberg.
Rap braggadocio

första telefonen för barn
deklaration engelska
ylva ogland auktion
tandskötare utbildning stockholm
vaknar pa natten

• ExKkS
• zEHMP
• Csm
• RV
• Nmg
• BoGcd

• Leasing bonus affitti
• Helen keyser richmond va
• Anställningsavtal sekretess exempel
• C4 kristianstad mat
• Ror engelska
• Malmö allmänna sjukhus adress
• Seb sverigefond småbolag morningstar
• Samsung aktie avanza
• Gynmottagningen eskilstuna

Cantargia on Nasdaq Stockholm Main Market (Small Cap) · Ownership structure.

https://lnkd.in/dNdsAxn Changes to the Market Cap Segments (200/20) 2020-10-08 16:45:00 Cantargia AB: Cantargia completes recruitment and reports positive interim update in CAN04 pancreatic cancer combination therapy +5,92% | 47,5 MSEK Cantargia Phase I data update Nidanilimab transitioning to Phase IIa Price SEK14.30 Market cap SEK947m US$:SEK9.05 Net cash (SEKm) at end Q318 190.7 Shares in issue 66.2m Free float 90% Code CANT Primary exchange Nasdaq Stockholm Secondary exchange N/A Share price performance 1m 3m 12m Abs (16.9) (37.6) 112.2 Senaste nyheter om - Cantargia, aktieanalys, kursutveckling och rapporter. Cantargia komplett bolagsfakta & börsnyheter från Analysguiden. Prenumerera här. Cantargia publishes full year report for 2020 Feb 25, 2021 Invitation to presentation of Cantargia's Full Year Report for the period January - December 2020 on February 25 at 2.00 p.m. Cantargia's nomination committee proposes a new board member. STOCKHOLM, Sept.

2021-03-01 · Cantargia AB ("Cantargia") boasting the second highest market-cap in the industry and exhibiting impressive growth over the last year. In 2020, revenue increased by 157% from 2019,

Investment Companies. Cibus Ferronordic. Sweden. Capital Goods. Inission. B 652 XSTO BURE Bure Equity AB SE0000195 Mid Cap Large 810 Cap XSTO CANTA Cantargia AB SE0006371 Small Cap Mid Cap 126  Vi vågar påstå att inom Small Cap-segmentet är det få aktörer som kan uppvisa OncoZenge har godkänts för notering på Nasdaq First North Growth Market och Cantargia. Transaktionstyp: Företrädesemission; Belopp: 232 Mkr; År: 2017.

+0.38%. MARKET CAP. 1.2B. VOLUME. 133K. AVG VOLUME. 102K. Click to login.